Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

34.00 +0.35 (+1.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
From AnaptysBio, Inc.
Via GlobeNewswire
Expert Ratings for AnaptysBio
Over the past 3 months, 4 analysts have published their opinion on AnaptysBio (NASDAQ:ANAB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
AnaptysBio to Participate in Upcoming November Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
From AnaptysBio, Inc.
Via GlobeNewswire
HC Wainwright Sees 40% Upside For This Once Battered Stock With Pipeline Turnaround
 
Via Benzinga
AnaptysBio Sells Royalty Interest In Cancer Drug For $45M
 
Via Benzinga
Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial
 
Via Benzinga
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
From AnaptysBio, Inc.
Via GlobeNewswire
Short Volatility Alert: AnaptysBio, Inc.
On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB) experienced volatile short activity. After the activity, the stock price went down -3.95% to $19.19. The overall sentiment... 
Via Benzinga
This Analyst Slashes PT On Rent the Runway By Around 43%, Plus JP Morgan Predicts $84 For Oracle
Credit Suisse cut the price target for Rent the Runway, Inc. (NASDAQ: RENT) from $7 to $4. Rent the Runway shares fell 30.6% to trade at $3.42 on Tuesday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022
Upgrades See all analyst ratings upgrades. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
Upgrades 
Via Benzinga
AnaptysBio Faces Another Setback For Imsidolimab, Stalls Work In Skin Scarring Indication
AnaptysBio Inc (NASDAQ: ANAB) announced topline data from its HARP Phase 2 trial of imsidolimab for moderate-to-severe hidradenitis suppurativa (HS).  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
AnaptysBio's Return On Capital Employed Insights
Benzinga Pro data, AnaptysBio (NASDAQ:ANAB) reported Q1 sales of $970.00 thousand. Earnings fell to a loss of $36.26 million, resulting in a 11.42% decrease from last quarter. 
Via Benzinga
AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers
 
Via Benzinga
Recap: AnaptysBio Q4 Earnings
AnaptysBio (NASDAQ:ANAB) reported its Q4 earnings results on Monday, March 7, 2022 at 09:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2022
Upgrades For Procter & Gamble Co (NYSE:PG), Truist Securities upgraded the previous rating of Hold to Buy. For the second quarter, Procter & Gamble had an EPS of $1.66,... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne
AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne  
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Sigilon Therapeutics (NASDAQ:SGTX) stock rose 15.5% to $1.49 during Monday's after-market session. The market value of their outstanding shares is at $48.1 million. 
Via Benzinga
AnaptysBio's Return On Capital Employed Insights
AnaptysBio (NASDAQ:ANAB) brought in sales totaling $1.01 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 388.12%, resulting in a loss of... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.